, a bio/informatics shared resource is still "open for business" - Visit the CDS website

Perlecan domain V inhibits α2 integrin-mediated amyloid-β neurotoxicity.

Wright S, Parham C, Lee B, Clarke D, Auckland L, Johnston J, Lawrence AL, Dickeson SK, Santoro SA, Griswold-Prenner I, Bix G
Neurobiol Aging. 2012 33 (7): 1379-88

PMID: 21126803 · DOI:10.1016/j.neurobiolaging.2010.10.018

Amyloid-β (Aβ) peptide is a key component of amyloid plaques, one of the pathological features of Alzheimer's disease. Another feature is pronounced cell loss in the brain leading to an enlargement of the ventricular area and a decrease in brain weight and volume. Aβ plaque deposition and neuronal toxicity can be modeled by treating human cortical neuronal cultures with Aβ and showing robust Aβ deposition and neurotoxicity that is mediated by α2β1 and αvβ1 integrins. The current study expands on these findings by showing that the domain V of perlecan, a known α2 integrin ligand, inhibits Aβ neurotoxicity in an α2 integrin-dependent manner. Additionally, Aβ binds more efficiently to cells expressing activated α2 integrin. Finally the inhibition of Aβ neurotoxicity with domain V is synergistic with inhibitors of αv integrin and β1 integrin. We propose that domain V and potentially other α2 integrin ligands could be a new therapeutic approach for inhibiting the Aβ plaque deposition and neurotoxicity observed in Alzheimer's disease.

Copyright © 2012 Elsevier Inc. All rights reserved.

MeSH Terms (14)

Amyloid beta-Peptides Animals Cells, Cultured Cerebral Cortex Heparan Sulfate Proteoglycans Humans Integrin alpha2 Ligands Mice Mice, Inbred C57BL Mice, Knockout Peptide Fragments Protein Binding Protein Structure, Tertiary

Connections (2)

This publication is referenced by other Labnodes entities: